IL134345A0 - Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon - Google Patents

Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon

Info

Publication number
IL134345A0
IL134345A0 IL13434598A IL13434598A IL134345A0 IL 134345 A0 IL134345 A0 IL 134345A0 IL 13434598 A IL13434598 A IL 13434598A IL 13434598 A IL13434598 A IL 13434598A IL 134345 A0 IL134345 A0 IL 134345A0
Authority
IL
Israel
Prior art keywords
multiple sclerosis
methods
treatment
consensus interferon
patients afflicted
Prior art date
Application number
IL13434598A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL134345A0 publication Critical patent/IL134345A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13434598A 1997-08-15 1998-07-15 Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon IL134345A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PCT/US1998/014622 WO1999008702A1 (fr) 1997-08-15 1998-07-15 Methodes de traitement de patients soufrant de sclerose en plaques, a l'aide d'interferon-consensus

Publications (1)

Publication Number Publication Date
IL134345A0 true IL134345A0 (en) 2001-04-30

Family

ID=25431058

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13434598A IL134345A0 (en) 1997-08-15 1998-07-15 Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL134345A IL134345A (en) 1997-08-15 2000-02-02 Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134345A IL134345A (en) 1997-08-15 2000-02-02 Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus

Country Status (17)

Country Link
US (1) US6013253A (fr)
EP (1) EP1003546B1 (fr)
JP (1) JP3813440B2 (fr)
KR (1) KR100415636B1 (fr)
CN (1) CN1183963C (fr)
AT (1) ATE338563T1 (fr)
AU (1) AU741074B2 (fr)
CA (1) CA2299361C (fr)
CY (1) CY1107314T1 (fr)
DE (1) DE69835823T2 (fr)
DK (1) DK1003546T3 (fr)
ES (1) ES2267188T3 (fr)
HU (1) HU229045B1 (fr)
IL (2) IL134345A0 (fr)
PT (1) PT1003546E (fr)
TW (1) TW474817B (fr)
WO (1) WO1999008702A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
EP1401808B1 (fr) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Peptidomimetiques et analogues de gpe
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
WO2004035086A2 (fr) * 2002-10-16 2004-04-29 Hunter Samuel F Technique de traitement par demyelinisation de maladie du systeme nerveux central
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
ZA200609412B (en) * 2004-05-17 2008-07-30 Ares Trading Sa Hydrogel interferon formulations
JP4988562B2 (ja) 2004-06-01 2012-08-01 アレス トレーディング ソシエテ アノニム 安定化したインターフェロン液体製剤
CA2567309A1 (fr) 2004-06-01 2005-12-15 Ares Trading S.A. Procede de stabilisation de proteines
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
WO2006119170A2 (fr) * 2005-05-02 2006-11-09 Avigen, Inc. Utilisation de peptides derives de cytokine pour traiter la douleur et une maladie neurodegenerative
WO2007022799A1 (fr) 2005-08-26 2007-03-01 Ares Trading S.A. Procede de preparation d'interferon beta glycosyle
EA013816B1 (ru) * 2005-09-01 2010-08-30 Арес Трейдинг С.А. Лечение неврита зрительного нерва
WO2007135172A2 (fr) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Régime à base de cladribine pour traiter la sclérose en plaques
JP5563475B2 (ja) * 2007-12-20 2014-07-30 メルク セローノ ソシエテ アノニム Ｐｅｇインターフェロン−ベータ製剤
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
WO2013008102A2 (fr) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Procédés et compositions pour évaluer et/ou traiter des maladies immunitaires chroniques
PL3369435T3 (pl) 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон
AR113906A1 (es) 2017-11-24 2020-06-24 Merck Patent Ges Mit Beschraenkter Haftung Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple
BR112023003432A2 (pt) 2020-09-10 2023-03-21 Merck Patent Gmbh Regime de tratamento para o tratamento de doenças autoimunes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
EP0502956B1 (fr) * 1989-11-29 1997-04-23 Amgen Boulder Inc. Production d'inhibiteur d'interleukine-1 humaine recombinee
WO1991017184A1 (fr) * 1990-04-27 1991-11-14 The Upjohn Company Inhibiteurs ameliores d'interleukine-1
AU660633B2 (en) * 1990-10-17 1995-07-06 Amgen, Inc. Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
ATE188610T1 (de) * 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
CA2157782A1 (fr) * 1993-03-08 1994-09-15 Joseph C. Glorioso Transfert de gene pour le traitement d'un tissu conjonctif chez un mammifere hote
EP0689449B1 (fr) * 1993-03-19 2002-10-30 Vacsyn S.A. Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
DE69521880T2 (de) * 1994-02-08 2002-01-03 Amgen Inc., Thousand Oaks Orales verabreichungssystem von chemischmodifizierten proteinen g-csf

Also Published As

Publication number Publication date
CN1183963C (zh) 2005-01-12
HUP0002755A3 (en) 2001-11-28
CA2299361A1 (fr) 1999-02-25
AU741074B2 (en) 2001-11-22
CY1107314T1 (el) 2012-11-21
ATE338563T1 (de) 2006-09-15
CA2299361C (fr) 2009-09-29
CN1267225A (zh) 2000-09-20
US6013253A (en) 2000-01-11
WO1999008702A1 (fr) 1999-02-25
DE69835823T2 (de) 2007-08-09
DE69835823D1 (de) 2006-10-19
KR100415636B1 (ko) 2004-01-24
KR20010030563A (ko) 2001-04-16
IL134345A (en) 2011-03-31
JP3813440B2 (ja) 2006-08-23
EP1003546B1 (fr) 2006-09-06
TW474817B (en) 2002-02-01
HUP0002755A2 (hu) 2000-12-28
PT1003546E (pt) 2006-12-29
EP1003546A1 (fr) 2000-05-31
ES2267188T3 (es) 2007-03-01
HK1030157A1 (en) 2001-04-27
DK1003546T3 (da) 2006-10-30
HU229045B1 (en) 2013-07-29
AU8300698A (en) 1999-03-08
JP2001515047A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
KR100321467B1 (fr)
CA2334267A1 (fr) Utilisation de peg-ifn-alpha et de ribavirine pour traiter l'hepatite c chronique
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
IL108114A0 (en) Therapeutic potentiated interferon combination
GB9806632D0 (en) Peptide factor
IL161889A (en) Use of omega interferon in the manufacture of a medicament for treating viral disease
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
IL130785A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
NZ514629A (en) PEGylated interferon-alpha administered at about 4.5- 9.0 micrograms/kg/week as a renal cell carcinoma treatment
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
MY119359A (en) Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis.
GB9903091D0 (en) Therapeutic nucleoside compound
GEP19991514B (en) Method for Treatment with Interferon
WO2003059334A3 (fr) Gemcitabine pour traiter la variole
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
EP1908477A3 (fr) Combinaison de témozolomide et interféron alpha pégylé pour le traitement du cancer
UA10279A (uk) Спосіб лікування дитячого церебрального паралічу

Legal Events

Date Code Title Description
FF Patent granted